Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

3.0K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
3.0K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

4.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.3K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship01:29

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

2.9K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.9K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

2.3K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
2.3K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

4.0K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
4.0K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

1.8K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiometabolic and anxiogenic consequences of chronic social defeat stress in male mice.

Neurobiology of stress·2025
Same author

Acute Postural Effects of Spinal Cord Injury: Dual Neural Opioid and Endocrine Non-Opioid Mechanism.

Cells·2025
Same author

Editorial related to the special issue: "Extrarenal functions of the renin-angiotensin-system".

Acta physiologica (Oxford, England)·2025
Same author

Neurons of the Central Nucleus of the Amygdala That Express Angiotensin Type 2 Receptors Couple Lowered Blood Pressure with Anxiolysis in Male Mice.

The Journal of neuroscience : the official journal of the Society for Neuroscience·2025
Same author

Phosphoproteomics for studying signaling pathways evoked by hormones of the renin-angiotensin system: A source of untapped potential.

Acta physiologica (Oxford, England)·2025
Same author

Inhibition of IRAP Enhances the Expression of Pro-Cognitive Markers Drebrin and MAP2 in Rat Primary Neuronal Cells.

International journal of molecular sciences·2024

Related Experiment Video

Updated: Feb 28, 2026

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography
09:09

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography

Published on: September 20, 2016

12.0K

Small-molecule AT2 receptor agonists.

Mathias Hallberg1, Colin Sumners2, U Muscha Steckelings3

  • 1The Beijer Laboratory, Department of Pharmaceutical Biosciences, BMC, Uppsala University, P.O. Box 591, SE751 24, Uppsala, Sweden.

Medicinal Research Reviews
|June 14, 2017
PubMed
Summary
This summary is machine-generated.

Researchers discovered compound 21 (C21), a selective small-molecule angiotensin II type 2 receptor (AT2R) agonist. This drug-like molecule exhibits high affinity for AT2R and is widely studied in various models.

Keywords:
AT2 receptorangiotensin IIpeptidomimeticsrenin-angiotensin system

More Related Videos

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.3K
Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development
07:56

Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development

Published on: January 26, 2018

17.4K

Related Experiment Videos

Last Updated: Feb 28, 2026

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography
09:09

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography

Published on: September 20, 2016

12.0K
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.3K
Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development
07:56

Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development

Published on: January 26, 2018

17.4K

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Molecular Biology

Background:

  • The angiotensin II type 2 receptor (AT2R) is a G protein-coupled receptor involved in various physiological processes.
  • Selective small-molecule modulators of AT2R are valuable tools for studying its function and potential therapeutic applications.

Purpose of the Study:

  • To describe the discovery and characterization of compound 21 (C21), the first selective small-molecule agonist for the AT2R.
  • To investigate the structure-activity relationships (SAR) of C21 and related compounds.
  • To summarize the pharmacological actions of C21.

Main Methods:

  • Synthesis and characterization of sulfonylcarbamate derivatives, including compound 8 (C21).
  • Binding assays to determine affinity for the AT2R (Ki = 0.4 nM).
  • Structure-activity relationship studies focusing on biaryl scaffolds and substituent effects.
  • Evaluation of pharmacological actions in vitro and in vivo models.

Main Results:

  • Compound 8 (C21), a sulfonylcarbamate derivative with a phenylthiofen scaffold, was identified as a potent and selective AT2R agonist (Ki = 0.4 nM).
  • Detailed SAR studies elucidated key structural features required for AT2R agonism and antagonism.
  • The pharmacological profile of C21 was summarized, highlighting its potential as a research tool.

Conclusions:

  • Compound 21 (C21) represents a significant advancement as the first selective small-molecule AT2R agonist.
  • The SAR data provides valuable insights for the design of novel AT2R ligands.
  • C21 is a promising tool for further investigation of AT2R's role in health and disease.